Introduction
Protein phosphorylation is a central regulatory strategy to alter the cellular functions, and protein kinases catalyze the transfer of the γ-phosphate of adenosine triphosphate (ATP) to acceptor proteins. Protein tyrosine kinases (PTKs) are critical regulators of cell proliferation, invasion, metastasis and cell survival (Edward & Sausville, 1999) . Two classes of PTKs are present in cells, the receptor protein tyrosine kinases (RTKs) and the non-receptor protein tyrosine kinases NRTKs lack receptor-like features such as an extracellular ligand-binding domain and a transmembrane spanning region, and most NRTKs are localized in the cytoplasm (Neet & Hunter, 1996) . NRTKs are anchored to the cell membrane through amino terminal modification, such as myristoylation or palmitoylation. In addition to a tyrosine kinase domain, NRTKs possess domains that mediate protein-protein, protein-lipid and protein-DNA interactions. The most commonly found protein-protein interaction domains in NRTKs are the Src homology 2 (SH2) and Src homology 3 (SH3) domains (Kuriyan & Cowburn, 1997) . The SH2 domain is a compact domain of 100 amino acid residues that binds phosphotyrosine residues in a sequence-specific manner. The smaller SH3 domain (60 residues) binds proline rich containing sequences capable of forming a polyproline type II helix. Some NRTKs lack SH2 and SH3 domains but possess subfamily-specific domains used for protein-protein interactions. For example, members of the Jak family contain specific domains that target them to the cytoplasmic portion of cytokine receptors. The NRTK Fak possesses two domains that mediate proteinprotein interactions; an integrin-binding domain and a focal adhesion-binding domain. The NRTK Bcr-Abl contains a nuclear localization signal but is found in both the nucleus and the cytoplasm. In addition to SH2 and SH3 domains, Bcr-Abl possesses an F actin-binding domain and a DNA-binding domain (Stevan & Till, 2000) .
A number of diseases, including cancer, diabetes and inflammation, are linked to perturbation of protein kinase mediated cell signaling pathways.
Therefore, protein kinases are targets for treatment of a number of diseases. BcrAbl kinase is NRTK, that is expressed in a wide range of cells and it is localized at several subcellular sites, including the nucleus, cytoplasm, mitochondria, endoplasmic reticulum and cell cortex, where Bcr-Abl interacts with a large variety of cellular proteins, including signaling adaptors, kinases, phosphatases, cell-cycle regulators, transcription factors and cytoskeletal proteins (Pendergast, 2002) . The
Bcr-Abl gene was first identified as the cellular homolog of the transforming gene of Abelson murine leukaemia and subsequently found to be involved in the Philadelphia chromosome translocation in human leukaemia and to encode a nonreceptor tyrosine kinase (Wong & Witte, 2004; Hantschel & Superti-Furga, 2004; Sawyers & Druker, 1999) .
Bcr-Abl is an oncogene that arises from fusion of the Bcr (breakpoint cluster region) gene with the c-Abl proto-oncogene. The Philadelphia chromosome involves fusion of the Bcr gene on chromosome 22 at band q11 with the Abl protooncogene on chromosome 9 at band q34 (Rowley, 1973) . Three different Bcr-Abl variants can be formed, depending on the amount of Bcr gene included: p185, p210
and p230. The three variants are associated with distinct types of human leukemia.
90% of chronic myelogenous leukemia (CML) and p230 with a subset of patients with chronic neutrophilic leukemia (CNL) (Melo, 1996) . The oncogenic ability of Bcr-Abl requires deregulated tyrosine kinase activity which leads to the recruitment of adaptor molecules, phosphorylation of signaling molecules and activation of downstream signaling events (Lugo et al., 1990; Daley et al., 1990) .
The NRTK Bcr-Abl kinase is a causative agent of CML and inhibiting the Bcr-Abl kinase enzyme might induce the apoptosis of the diseased cells from the patient's body. In 1996, Novartis team (Druker et al., 1996) reported a successful
Bcr-Abl inhibitor, CGP57148, which is later renamed STI-571, Gleevec or imatinib.
Imatinib is a specific inhibitor that binds with high affinity to the inactive conformation of the Bcr-Abl tyrosine kinase and has been shown to be effective in the treatment of CML with little toxicity, compared to other cancer therapies (Schindler et al., 2000; Druker et al., 2001a; O'Brien et al., 2003) . In addition to its ability to block Bcr-Abl, imatinib also inhibits the platelet-derived growth factor (PDGF) receptor and the c-Kit receptor (Druker et al., 2001b; Buchdunger et al., 2000) . c-Kit is the cellular homolog of the v-kit retroviral oncogene and the c-Kit gene product is expressed in hematopoietic progenitor cells, mast cells, germ cells, interstitial cells of cajal and some human tumors (Nocka et al.,1989) . CML represents the first human malignancy to be successfully treated with a small molecule inhibitor, imatinib. In spite of its several virtues, clinical resistance to imatinib has been reported in small number of patients due to Bcr-Abl gene mutation or amplification. Although some of these mutations are located close to the imatinib-binding site, most of the mutations occur at distal positions. A plausible mechanism for the induction of resistance by these mutations involves the destabilization of the inactive conformation, with concomitant preservation of the catalytic capabilities of the kinase domain (Shah et al., 2002) .
A significant progress for the treatment of patients with resistance to imatinib is the identification of inhibitors that can bind to both active and inactive conformations of Bcr-Abl kinase and those that bind preferably to the active form and provide a way to oppose the mutation-induced resistance to imatinib. Other mechanisms of imatinib resistance include Bcr-Abl gene amplification (Gadzicki et al., 2005) . In order to overcome the resistance to imatinib, a number of new inhibitors have been synthesized. The most effective ATP mimics are AMN107 (Weisberg et al., 2005) and BMS-354825, which inhibit almost all imatinib resistant forms of Bcr-Abl (Shah et al., 2004; Doggrell, 2005) but are not effective against the T315I mutant. The T315I mutation is the most common mutation found in patients undergoing imatinib therapy (Shah et al., 2002) and this is responsible role in determination of the inhibitor specificity (Liu, et al., 1999) and regulates the binding of inhibitors. Thr315 opens up an auxiliary binding site, which is occupied by the piperazinyl-substituted benzamide moiety of imatinib and participates through the hydroxymethylene side chain, in a crucial H bonding interaction between imatinib and Abl (Schindler et al., 2000) , as well as Bcr-Abl (Manley et al., 2002; Nagar et al., 2002) . Mutation to isoleucine abrogates the possibility of this H bonding interaction, which, combined with the additional bulk of the isoleucine side chain, sterically hinders imatinib binding and leads to imatinib insensitivity and consequently resistance in patients. This implies that it is particularly difficult to inhibit Bcr-Abl (T315I) with an ATPcompetitive compound (Carter et al., 2005) . The possibility of ATP competitive compounds is to bind either the wild-type Bcr-Abl or T315I mutant Bcr-Abl, but The crystal structure of VX-680 bound to the catalytic domain of Bcr-Abl (PDB_ID: 2F4J) containing a mutation (H396P) has been solved (Young et al., 2006) . This mutation confers imatinib resistance in Bcr-Abl kinase but is inhibited by VX-680 in vitro. It has been shown that VX-680 inhibits Bcr-Abl kinase activity in cells derived from patients carrying the T315I mutation in the kinase domain of Bcr-Abl, and that it retains activity towards purified T315I mutation in vitro. These results provide a structural explanation for the retention of inhibitory activity of VX-680 towards mutant proteins, which are no longer inhibited by imatinib. The structure of the kinase domain of Bcr-Abl (H396P) bound to VX-680 is shown in Figure 3 .1b.
This 3-D crystal structure (PDB_ID: 2F4J) is the source for the virtual screening strategy used to discover novel inhibitors to Bcr-Abl kinase. Virtual screening provides assurance to an inexpensive and fast alternative, to high throughput screening (HTS) in order to discover useful lead compounds for drug discovery projects (Jürgen, 2002) . Drug discovery methods such as structure-based virtual screening focuses on using the protein crystal structure and is exemplified by receptor-based docking methods such as affinity docking, FlexX, Autodock and GOLD. More recently, several new approaches have been described for pharmacophore screening that enable pharmacophore information to be included in the search query (Hahn, 1997; Putta et al., 2002) .
In this work we have generated a chemical function based pharmacophore of VX-680 using "View Hypotheses" module in catalyst software. This pharmacophore was used for the screening of databases such as, NCI, Maybridge and Derwent-WDI2005 and the obtained hits were docked into the Bcr-Abl kinase crystal structure using GOLD software (Jones et al., 1997) . Our goal is to search for molecules with alternative leads to the VX-680 in a commercially available database that would inhibit wild type and mutant Bcr-Abl kinases. The chemical component pharmacophoric hypotheses was built using the "View Hypotheses"
workbench within Catalyst using the conformation of VX-680-Bcr-Abl kinase interactions reported in the X-ray complex. This pharmacophoric query was used to search a multi-conformational databases using Catalyst. Finally, the molecules identified from virtual screening were docked into the Bcr-Abl kinase using GOLD software to observe the key interactions between the screened molecules and BcrAbl kinase and thus validate the hits as useful and novel Bcr-Abl kinase inhibitors.
Methods

Protein preparation:
The 3 In the first step all the hydrogen atoms were minimized, keeping the other atoms fixed. In the second step whole protein complex including crystal water was energy minimized by the steepest descent followed by conjugate gradient methods to achieve a convergence gradient of 0.01 kcal/mol using CVFF force fields in InsightII 2005. Crystallographic waters were retained for docking studies. In addition to this, we have mutated T315I in Biopolymer module and used the same methods for energy minimization in order to study the binding of these molecules to Bcr-Abl kinase (T315I) mutant.
Pharmacophore model generation:
From the crystal structure (PDB_ID: 2F4J), a ligand-based (VX-680) pharmacophore query was generated for Bcr-Abl kinase using View Hypotheses workbench module in Catalyst (Catalyst 4.11, Accelrys) using the conformation of VX-680 reported in the X-ray complex with Bcr-Abl kinase. In the hypotheses, two hydrogen bond donors (HD), two hydrogen bond acceptors (HA) and one hydrophobic interaction (HP) were allowed as observed in the protein structure. A maximum of 5 features were selected to construct the pharmacophore hypotheses.
This pharmacophore query was used for the virtual screening of small molecule databases and we identified 289 molecules form the NCI, Maybridge and Derwent-WDI2005 databases. These databases are multi-conformational Catalyst databases, which were built using the best option with the MAXCONFS option set to 250 and the energy threshold set to 15 kcal/mol.
Virtual screening:
The 
Docking:
The new lead molecules identified from virtual screening, were docked into the crystal structure of Bcr-Abl kinase (PDB_ID: 2F4J) using GOLD (GOLD 3.10, CCDC, UK) software. GOLD (Genetic Optimization of Ligand Docking) is a genetic algorithm for docking flexible ligands into protein binding site. The details were discussed in the section 2.2.5. During docking, the default algorithm speed was selected, and the ligand binding site in the Bcr-Abl kinase, was defined within a 10 Å radius with the centroid as Glu 316 main chain carbonyl oxygen atom. For docking, the number of poses for each inhibitor was set to ten, and early termination was allowed if the top five bound conformations of a ligand were within 1.5 Å (RMSD). After docking, the individual binding poses of each ligand were re-ranked according to the GOLD score. The top ranked conformation of each ligand was selected and analysed using SILVER (SILVER 1.1.1, CCDC, UK) to examine the mode of protein-inhibitor binding.
Hardware and software:
InsightII 2005 was used for energy minimization of Bcr-Abl kinase, and Catalyst 4.11 was used for pharmacophore generation and virtual screening on SGI Octane2 workstation equipped with 2600 MHz MIPS R14000 processors. The docking calculations using GOLD software and docking analysis using SILVER (Nissink et al., 2002) were carried out on an Intel P4-based windows system.
Results and Discussion
The aim of the present work is to identify novel lead molecules as inhibitors for Bcr-Abl kinase and its mutant (T315I). We have achieved this using pharmacophore model generation, virtual screening of small molecule databases and molecular docking studies.
Generation of pharmacophore model:
Our choice of pharmacophore features was based upon the conformation of VX-680 reported in the X-ray complex with Bcr-Abl kinase. Two hydrogen bond donor features were predicted to interact with the side chain amino group of 
Database screening:
The pharmacophore query generated above was used to screen NCI, Maybridge and Derwent-WDI2005 databases. In all, about 5000 molecules were obtained as hits from in silico screening (screen 1). To assess the drug-likeliness of these hits, a second screen, incorporating Lipinski's rule of 5 was used. A total of 1100 molecules were obtained as hits from this screen (Screen 2). To further increase the probability of the hit to be a lead, a fitness score >7.00 was used as the 
GOLD docking:
The crystal structure of Bcr-Abl kinase bound to substrate VX-680 (PDB_ID: 2F4J) was used for the docking studies. All amino acids within 10 Å radius from the Glu316 main chain carbonyl oxygen atom were considered to comprise the active site. Docking was carried out using GOLD 3.10 software. Docking calculations were carried out using two types of mutant proteins; these are Bcr-Abl (H396P) kinase and Bcr-Abl (T315I) kinase.
The inhibitor VX-680 was docked into the
Bcr-Abl (H396P) kinase docking:
The molecules obtained from virtual screening were docked into the Bcr- The interaction of Hit RJF00578 is shown in Figure 3. These results shows that the new molecules obtained from virtual screening form several non bonding interactions, and bind Bcr-Abl kinase in the VX-680 binding site. Further modifications of these lead molecules will generate inhibitors that bind Bcr-Abl kinase with high specificity.
Conclusions
1.
Using pharmacophore modeling and virtual screening, we have identified new lead molecules as Bcr-Abl kinase inhibitors.
2.
We have studied the binding of these inhibitors to Bcr-Abl kinase using docking methods and confirm that these molecules bind the VX-680 binding site of the enzyme.
3.
Further modifications and addition of suitable functional groups to these new scaffolds will generate high affinity Bcr-Abl kinase specific inhibitors.
4.
Using two mutant Bcr-Abl kinase proteins for docking, we have identified some useful molecules for drug resistant Bcr-Abl kinase protein.
5.
Our results confirm chemical function based virtual screening as a powerful tool to discover novel inhibitors of the protein kinase family, and further validate virtual screening as an inexpensive and efficient means for lead discovery.
